Gary R. Lichtenstein, MD Director, Center for IBD University of Pennsylvania Health System Professor of Medicine University of Pennsylvania School of Medicine Division of Gastroenterology Philadelphia, PA
AMA PRA Category 1 Credit™ Medium
NOTE: This activity was presented as a live visiting faculty grand rounds series beginning on September 22, 2015. Participants who received credit for attending any of the live presentations are not eligible to receive credit for this online release.
IBD is a chronic progressive inflammatory disorder of the GI tract, which includes Crohn’s disease (CD) and ulcerative colitis (UC). CD and UC are both lifelong conditions with substantial morbidity, including debilitating symptoms, frequent need of high-risk procedures such as surgery, and decreased health-related quality of life. Determining the best individualized treatment approach for patients with IBD is becoming increasingly complex with the availability of new medical therapies and evolving new treatment paradigms, and is generally challenging due to the complicated nature of both CD and UC. Clinicians must understand the risks and benefits of available treatment options, including new and emerging biologic agents, and be able to develop tailored regimens based on unique patient and disease factors and current evidence-based treatment goals. Program Developer/Facilitator
. Target Audience
This activity, developed by experts in IBD, has been designed for gastroenterologists, internal medicine/primary care physicians, nurse practitioners, physician assistants, nurses, and other clinicians involved in the treatment of patients with IBD.
Upon completion of this educational activity, the participant should be able to:
Discuss recent data that support the appropriate, early use of anti-TNF therapies.
Identify patients who are most likely to benefit from early and intensive treatment with anti-TNF therapies.
Formulate strategies to effectively manage common side effects of conventional IBD medications.
Implement strategies to increase patient adherence through interdisciplinary and patient communication.
Describe the appropriate postoperative use of medical therapies to prevent IBD recurrence.
Gary R. Lichtenstein, MD, discloses the following relationships with commercial interests:
Consultant: Abbott Corporation/AbbVie, Actavis, Alaven, Ferring, Hospira, Janssen Biotech, Luitpold/American Regent, Pfizer, Prometheus Laboratories, Romark, Salix Pharmaceuticals, Santarus, Shire Pharmaceuticals, Takeda, UCB, Warner Chilcott
Research/Grant Support: Ferring, Janssen Biotech, Prometheus Laboratories, Salix Pharmaceuticals, Santarus, Shire Pharmaceuticals, UCB, Warner Chilcott
Royalties/Patents: SLACK, Inc
Author/Editor Honoraria: Clinical Advances in Gastroenterology, Gastroenterology and Hepatology, Ironwood, Luitpold/American Regent, McMahon Publishing, Springer Science and Business Media, Up-To-Date
Funding to University of PA (IBD Fellow Education): Janssen Biotech
Rick Ricer, MD, Physician Reviewer, University of Cincinnati, has no conflicts of interest to disclose.
Susan P. Tyler, MEd, CMP, CHCP, FACEHP, University of Cincinnati, has no conflicts of interest to disclose.
Kathleen Hines, MCM Education Editorial Director, has no conflicts of interest to disclose.
The University of Cincinnati requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty reports his presentation will not contain reference to investigational and/or off-label uses.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT STATEMENT: The University of Cincinnati designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release date: December 11, 2015
Last review date: December 11, 2015
Expiration date: December 11, 2016 Commercial Support Statements
Supported by independent educational grants from AbbVie, Inc.; Shire Pharmaceuticals; and Prometheus Laboratories, Inc.
* Click "Start Program" below.
* Review the activity.
* Take the post-test and score at least 70%.
* You are allowed a total of 3 attempts.
* Complete the evaluation.
* View, print, or save a CME certificate verifying your
credit/participation in this activity.
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
There is no charge for CME credit.
© 2015 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the University of Cincinnati, AbbVie, Inc.; Shire Pharmaceuticals; or Prometheus Laboratories, Inc. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.